Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines...
Brief Summary
Official Title: “Extended-Release Niacin/Lovastatin Versus Usual Care for Treatment of Dyslipidemia in a Primary Care Setting (EXTEND Study)”
The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines.
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Detailed Clinical Trial Description
Both LDL and HDL are important contributors in the pathophysiology of atherosclerosis and coronary artery disease (CAD); however, HDL is often ignored in primary care. The combination of niacin extended-release (ER)/lovastatin in a single tablet formulation (Advicor®) may be the most effective therapeutic option for simultaneously correcting both of these lipoprotein abnormalities to reduce CAD risk. The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines.
Intervention(s) in this Clinical Trial
- Drug: Niacin Extended Release/Lovastatin
Outcome Measures for this Clinical Trial
Primary Measures
- Lipid parameter change at 3 and 6 months
- Percent of patients achieving ATP III LDL goals at 3 and 6 months
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- 1. >18 years old with CAD or risk factors for CAD
- 2. under standard care at Family Medical Care of Tulsa
- 3. not at LDL goal per ATP III guidelines
Exclusion Criteria:
- 1. pregnancy/lactating
- 2. liver disease
- 3. allergies to statin or niacin
- 4. active peptic ulcer disease
- 5. previous treatment with combination therapy for dyslipidemia
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: In His Image Other
Overall Clinical Trial Officials and Contacts
Jason A Logan, MD Principal Investigator In His Image Family Medicine Residency
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00345657
Study ID Number: IHI-A001
ClinicalTrials.gov Identifier: NCT00345657
Health Authority: United States: Institutional Review Board
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00345657
